AstraZeneca ROA 1992-2025 | AZN

Current and historical return on assets (ROA) values for AstraZeneca (AZN) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
AstraZeneca ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2025-06-30 $8.30B $112.42B 7.76%
2025-03-31 $7.78B $106.25B 7.41%
2024-12-31 $7.04B $104.04B 6.77%
2024-09-30 $6.50B $104.92B 6.30%
2024-06-30 $6.44B $104.34B 6.38%
2024-03-31 $6.33B $102.29B 6.39%
2023-12-31 $5.96B $101.12B 6.10%
2023-09-30 $5.90B $96.09B 6.12%
2023-06-30 $6.16B $96.54B 6.42%
2023-03-31 $4.71B $96.69B 4.90%
2022-12-31 $3.29B $96.48B 3.39%
2022-09-30 $2.04B $94.19B 2.06%
2022-06-30 $-1.25B $96.58B -1.22%
2022-03-31 $-1.06B $100.27B -1.10%
2021-12-31 $0.11B $105.36B 0.13%
2021-09-30 $1.47B $107.22B 1.88%
2021-06-30 $3.77B $73.64B 5.60%
2021-03-31 $3.98B $64.93B 6.22%
2020-12-31 $3.20B $66.73B 5.16%
2020-09-30 $2.50B $64.11B 4.12%
2020-06-30 $2.15B $59.93B 3.62%
2020-03-31 $1.52B $57.21B 2.54%
2019-12-31 $1.34B $61.38B 2.20%
2019-09-30 $2.06B $58.91B 3.39%
2019-06-30 $2.19B $61.89B 3.57%
2019-03-31 $2.41B $61.06B 3.94%
2018-12-31 $2.16B $60.65B 3.49%
2018-09-30 $2.42B $61.44B 3.88%
2018-06-30 $2.68B $61.34B 4.24%
2018-03-31 $2.80B $63.28B 4.38%
2017-12-31 $3.00B $63.35B 4.73%
2017-09-30 $3.54B $64.59B 5.60%
2017-06-30 $3.87B $65.12B 6.15%
2017-03-31 $3.39B $60.96B 5.40%
2016-12-31 $3.50B $62.53B 5.50%
2016-09-30 $2.47B $63.22B 3.91%
2016-06-30 $2.22B $64.42B 3.66%
2016-03-31 $2.92B $64.32B 5.00%
2015-12-31 $2.83B $60.06B 5.07%
2015-09-30 $1.70B $54.12B 3.06%
2015-06-30 $1.18B $55.17B 2.11%
2015-03-31 $1.28B $53.70B 2.25%
2014-12-31 $1.23B $58.60B 2.12%
2014-09-30 $1.03B $56.16B 1.79%
2014-06-30 $2.02B $58.54B 3.55%
2014-03-31 $2.05B $59.39B 3.67%
2013-12-31 $2.56B $55.90B 4.73%
2013-09-30 $4.59B $54.12B 8.57%
2013-06-30 $4.85B $53.99B 9.14%
2013-03-31 $5.63B $52.33B 10.73%
2012-12-31 $6.24B $53.53B 11.99%
2012-09-30 $6.23B $52.45B 12.01%
2012-06-30 $8.19B $51.39B 15.79%
2012-03-31 $8.71B $50.76B 16.62%
2011-12-31 $9.99B $52.83B 18.73%
2011-09-30 $10.13B $52.58B 18.70%
2011-06-30 $8.21B $53.41B 14.89%
2011-03-31 $8.21B $54.53B 14.81%
2010-12-31 $8.08B $56.13B 14.61%
2010-09-30 $8.01B $56.39B 14.56%
2010-06-30 $8.57B $54.65B 15.90%
2010-03-31 $8.16B $54.08B 15.46%
2009-12-31 $7.53B $54.92B 14.79%
2009-09-30 $7.22B $51.90B 14.77%
2009-06-30 $6.84B $50.20B 14.28%
2009-03-31 $6.75B $46.52B 14.10%
2008-12-31 $6.11B $46.78B 12.64%
2008-09-30 $6.14B $48.07B 12.62%
2008-06-30 $5.75B $50.20B 15.67%
2008-03-31 $5.53B $48.46B 15.35%
2007-12-31 $5.58B $47.96B 17.85%
2007-09-30 $5.75B $0.00B 21.47%
2007-06-30 $6.00B $47.60B 17.75%
2007-03-31 $6.20B $29.57B 21.38%
2006-12-31 $6.06B $29.93B 21.72%
2006-09-30 $5.85B $28.12B 21.94%
2006-06-30 $5.48B $28.46B 21.30%
2006-03-31 $5.10B $25.15B 20.53%
2005-12-31 $4.72B $24.84B 19.05%
2005-09-30 $4.46B $24.53B 17.87%
2005-06-30 $4.44B $24.88B 17.79%
2005-03-31 $4.06B $24.85B 16.37%
2004-12-31 $3.81B $25.62B 15.54%
2004-09-30 $3.48B $24.52B 14.49%
2004-06-30 $3.07B $24.10B 12.99%
2004-03-31 $2.91B $23.90B 12.54%
2003-12-31 $3.04B $23.57B 13.31%
2003-09-30 $2.83B $23.05B 12.68%
2003-06-30 $2.95B $22.15B 13.59%
2003-03-31 $3.06B $22.50B 14.42%
2002-12-31 $3.09B $21.58B 15.01%
2002-09-30 $3.42B $20.58B 17.37%
2002-06-30 $3.22B $20.20B 16.78%
2002-03-31 $3.15B $19.96B 16.95%
2001-12-31 $2.97B $17.99B 16.26%
2001-09-30 $2.74B $18.51B 14.93%
2001-06-30 $2.68B $17.83B 19.51%
2001-03-31 $2.65B $18.69B 28.58%
2000-12-31 $2.59B $18.43B 56.20%
2000-06-30 $2.10B $0.00B 29.15%
2000-03-31 $1.89B $0.00B 26.27%
1998-12-31 $2.61B $8.97B 116.41%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $218.471B $44.351B
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $495.141B 66.87
Johnson & Johnson (JNJ) United States $450.090B 16.68
Novo Nordisk (NVO) Denmark $424.453B 49.78
Merck (MRK) United States $270.018B 37.87
AbbVie (ABBV) United States $264.086B 11.85
Novartis AG (NVS) Switzerland $218.425B 15.54
Pfizer (PFE) United States $201.199B 7.39
Sanofi (SNY) $132.955B 11.89
Innoviva (INVA) United States $0.953B 10.12